Prof. Mark Middleton trained in Medicine at the Universities of Cambridge and Oxford, and in Oncology at the Christie Hospital and University of Manchester. His clinical and research interests are in new cancer drug development and the treatment of upper GI cancers and melanoma. He has been Chief or Principal Investigator on over 100 trials and is closely involved in the development of new therapies including DNA repair, immune checkpoint and kinase inhibitors, ImmTACs and oncolytic viruses. Mark is Director of the CRUK Oxford Centre and Head of Oncology at the University of Oxford, where he founded the Early Phase Clinical Trials Unit.
He is interested in the development of new drugs to treat cancer, principally immunotherapies. To achieve this he works with scientists and drug companies to validate drug targets, optimise candidate molecules and design both pre-clinical testing programmes and early clinical trials, with the aim of bringing these trials to patients in Oxford.
Photo: Getty Images